Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 12/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | CSF1R | P07333 | 6/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potrasertib SCHEMBL29859319 | 1.00 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| Potrasertib SCHEMBL21373352 | 1.00 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| Potrasertib SCHEMBL29506543 | 1.00 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| Potrasertib SCHEMBL27123597 | 1.00 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| SCHEMBL29506471 | 0.95 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| SCHEMBL21373331 | 0.95 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| SCHEMBL30732422 | 0.95 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| SCHEMBL27131392 | 0.95 | WEE1 (0.63) | WEE1KCNH2EGFRCSF1RJAK2 | |
| Potrasertib SCHEMBL23246122 | 0.95 | WEE1 (0.61) | WEE1KCNH2EGFRCSF1RJAK2 | |
| SCHEMBL21373333 | 0.95 | WEE1 (0.59) | WEE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | claimed |
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | Impact Therapeutics (Shanghai), Inc (CN) | 2024-03-21 | — | — | US | disclosed |
| US-20240010655-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | Impact Therapeutics (Shanghai), Inc (CN) | 2024-01-11 | — | — | US | disclosed |
| WO-2021073491-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | 上海瑛派药业有限公司 | 2021-04-22 | — | — | WO | disclosed |
| WO-2021073491-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | 上海瑛派药业有限公司 | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240091233-A1 | USE OF WEE1 KINASE INHIBITORS IN THE TREATMENT OF CANCER | WEE1, WEE2, EZH2 | WEE1 1/4885KCNH2 3809/4885EGFR 554/4885 |
| US-20240010655-A1 | DIHYDROIMIDAZO PYRIMIDO PYRIMIDINONE COMPOUND | WEE1, WEE2, NME1 | WEE1 1/4885KCNH2 3857/4885EGFR 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.